Related Experiment Video

Updated: Jun 13, 2026

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective
06:14

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective

Published on: January 12, 2024

2.9K

Treatment patterns of biologic disease-modifying anti-rheumatic drugs in juvenile idiopathic arthritis: a

Jong Gyun Ahn1,2, Min-Taek Lee3, Daye Lee4

  • 1Department of Pediatrics, Severance Children's Hospital, Seoul, Korea.

Journal of Rheumatic Diseases
|March 27, 2026
PubMed

Insights

This study analyzed juvenile idiopathic arthritis (JIA) treatment patterns in Korea, finding etanercept most common among biologic DMARDs. Understanding these real-world trends aids optimizing care for children with JIA.

Area of Science:

  • Rheumatology
  • Pediatrics
  • Real-world evidence

Background:

  • Juvenile idiopathic arthritis (JIA) is a common childhood chronic arthritis with unknown etiology.
  • Biologic disease-modifying anti-rheumatic drugs (bDMARDs) improve outcomes in severe JIA but face challenges due to disease heterogeneity.
  • Understanding novel therapy patterns is crucial for optimizing JIA management.

Purpose of the Study:

  • To investigate the real-world treatment patterns of bDMARDs in Korean JIA patients.
  • To compare treatment strategies between bDMARD and non-bDMARD groups.

Main Methods:

  • Retrospective analysis of Korean national claims data (2007-2019).
  • Classification of JIA patients into bDMARD and non-bDMARD groups.
  • Comparison of treatment patterns, including drug choices and discontinuation rates.

Main Results:

  • 31.3% of 1,728 JIA patients received bDMARDs; 15.5% discontinued.
  • Etanercept (69.7%) was the most frequent first bDMARD, followed by adalimumab and tocilizumab.
  • Conventional synthetic DMARDs (csDMARDs) were used by 68.7% of the non-bDMARD group, with higher discontinuation rates (46.6%).

Conclusions:

  • This study provides the first comprehensive profile of JIA treatment patterns in Korea using population-based claims data.
  • Findings enhance understanding of real-world treatment trends for JIA.
  • The results can aid clinical decision-making in managing JIA.
Abstract

Keywords:
Antirheumatic agentsDisease-modifying antirheumatic drugJuvenile idiopathic arthritis

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.3K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...